Uniqure NV
QURE13.960USD
+0.265+1.94%
Market hours （ET）Quotes delayed by 15 min
765.92MMarket Cap
LossP/E TTM
More Details of Uniqure NV Company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Info
Ticker SymbolQURE
Company nameUniqure NV
IPO dateFeb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
Number of employees209
Security typeOrdinary Share
Fiscal year-endFeb 05
AddressPaasheuvelweg 25a
CityAMSTERDAM
Stock exchangeNASDAQ Global Select Consolidated
CountryNetherlands
Postal code1105 BP
Phone31202406000
Websitehttps://www.uniqure.com/
Ticker SymbolQURE
IPO dateFeb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
Shareholders
Shareholders
Proportion
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
47.15%
Hedge Fund
23.24%
Investment Advisor
15.35%
Corporation
4.36%
Research Firm
3.09%
Venture Capital
2.58%
Individual Investor
1.72%
Private Equity
0.84%
Bank and Trust
0.06%
Other
1.60%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
394
54.93M
100.44%
-2.00M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
2023Q1
454
47.06M
99.04%
-12.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vestal Point Capital, LP
4.79M
8.75%
+1.77M
+58.43%
Mar 31, 2025
RTW Investments L.P.
4.27M
7.79%
+3.36M
+372.04%
Mar 31, 2025
EcoR1 Capital, LLC
3.99M
7.29%
+588.97K
+17.32%
Mar 31, 2025
Nantahala Capital Management, LLC
2.76M
5.03%
+302.60K
+12.33%
Mar 31, 2025
abrdn Inc.
2.22M
4.05%
+706.22K
+46.79%
Mar 31, 2025
Bristol Myers Squibb
2.39M
4.36%
--
--
Sep 30, 2024
Avoro Capital Advisors LLC
2.17M
3.97%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.99M
3.63%
--
--
Mar 31, 2025
Two Sigma Investments, LP
1.58M
2.9%
-50.79K
-3.10%
Mar 31, 2025
683 Capital Management LLC
1.55M
2.83%
+25.00K
+1.64%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Dorsey Wright Healthcare Momentum ETF
1.53%
WisdomTree BioRevolution Fund
1.09%
Global X Genomics & Biotechnology ETF
0.88%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Main Thematic Innovation ETF
0.46%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
View more
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.53%
WisdomTree BioRevolution Fund
Proportion1.09%
Global X Genomics & Biotechnology ETF
Proportion0.88%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.78%
Main Thematic Innovation ETF
Proportion0.46%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
SPDR S&P Biotech ETF
Proportion0.24%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
